TY - JOUR
T1 - NMR-based exploration of the acceptor binding site of human blood group B galactosyltransferase with molecular fragments
AU - Rademacher, Christoph
AU - Landström, Jens
AU - Sindhuwinata, Nora
AU - Palcic, Monica M.
AU - Widmalm, Göran
AU - Peters, Thomas
N1 - Funding Information:
Acknowledgment This work was supported by grants from the Swedish Research Council (VR), The Knut and Alice Wallenberg Foundation and Magn. Bergvalls Stiftelse (G.W.). J.L. acknowledges the Deutscher Akademischer Austausch Dienst and the Swedish Institute for financial support. T.P. acknowledges grants the German Research Council (DFG, HBFG 101/192-1 and ME 1830/1), from the state of Schleswig-Holstein (Innovationsfonds 2005), and from the University of Lübeck. C.R. thanks the Fonds der Chemischen Industrie for a stipend. N.S. thanks the Studienstiftung des Deutschen Volkes for a stipend.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/4
Y1 - 2010/4
N2 - A substantial body of work has been devoted to the design and synthesis of glycosyltransferase inhibitors. A major obstacle has always been the demanding chemistry. Therefore, only few potent and selective inhibitors are known to date. Glycosyltransferases possess two distinct binding sites, one for the donor substrate, and one for the acceptor substrate. In many cases binding to the donor site is well defined but data for acceptor binding is sparse. In particular, acceptor binding sites are often shallow, and in many cases the dimensions of the binding pocket are not well defined. One approach to glycosyltransferase inhibitors is to chemically link donor site and acceptor site ligands to generate high affinity binders. Here, we describe a novel approach to identify acceptor site ligands from a fragment library. We have chosen human blood group B galactosyltransferase (GTB) as a biologically important model target. The approach utilizes a combination of STD NMR, spin-lock filtered NMR experiments and surface plasmon resonance measurements. Following this route we have identified molecular fragments from a fragment library that bind to the acceptor site of GTB with affinities of the order of a natural acceptor substrate. Unlike natural substrates these fragments allow for straightforward chemical modifications and, therefore will serve as scaffolds for potent GTB inhibitors. In general, the approach described is applicable to any glycosyltransferase and may assist in the development of novel glycosyltransferase inhibitors.
AB - A substantial body of work has been devoted to the design and synthesis of glycosyltransferase inhibitors. A major obstacle has always been the demanding chemistry. Therefore, only few potent and selective inhibitors are known to date. Glycosyltransferases possess two distinct binding sites, one for the donor substrate, and one for the acceptor substrate. In many cases binding to the donor site is well defined but data for acceptor binding is sparse. In particular, acceptor binding sites are often shallow, and in many cases the dimensions of the binding pocket are not well defined. One approach to glycosyltransferase inhibitors is to chemically link donor site and acceptor site ligands to generate high affinity binders. Here, we describe a novel approach to identify acceptor site ligands from a fragment library. We have chosen human blood group B galactosyltransferase (GTB) as a biologically important model target. The approach utilizes a combination of STD NMR, spin-lock filtered NMR experiments and surface plasmon resonance measurements. Following this route we have identified molecular fragments from a fragment library that bind to the acceptor site of GTB with affinities of the order of a natural acceptor substrate. Unlike natural substrates these fragments allow for straightforward chemical modifications and, therefore will serve as scaffolds for potent GTB inhibitors. In general, the approach described is applicable to any glycosyltransferase and may assist in the development of novel glycosyltransferase inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=77952099549&partnerID=8YFLogxK
U2 - 10.1007/s10719-010-9282-5
DO - 10.1007/s10719-010-9282-5
M3 - Journal articles
C2 - 20217221
AN - SCOPUS:77952099549
SN - 0282-0080
VL - 27
SP - 349
EP - 358
JO - Glycoconjugate Journal
JF - Glycoconjugate Journal
IS - 3
ER -